Allergic Asthma Therapeutics Market Synopsis:
Allergic Asthma Therapeutics Market Size was valued at USD 26.4 Billion in 2023, and is Projected to Reach USD 41.66 Billion by 2032, Growing at a CAGR of 5.2% From 2024-2032.
The Allergic Asthma Therapeutics Market can be described as the market for drugs intended to cure allergic asthma – a long-term illness of the respiratory tricuspid system which results from the exposure to allergens like pollen, dust, mold, or pet dander. Market includes drugs that are used to relieve conditions including wheezing, coughing, shortness of breath and chest constriction. Available therapies include, anti-inflammatory agents, bronchodilators, biologicals and combination therapies designed to prevent inflammation, widen the airways and minimize life threatening asthmatic episodes.
The major factor that contributing to the growth of the Allergic Asthma Therapeutics Market is the growing incidence of allergic asthma around the world and particularly within developing countries. Some of the causes include, pollution, lack of exercise, and increased incidences of exposure to allergic triggers. As knowledge of the disease and its path increases, as well as the experience in the treatment of asthma, the creation of new targeted products contributes to market growth.
Combined with this has been the ever-growing need for biologic and monoclonal antibodies that are more effective and tailored towards the individual. These treatment regiments are expensive but in return they have provided better results in terms of patient prognosis and hence have continued to be embraced in clinical practice thus fueling market potential.
Allergic Asthma Therapeutics Market Trend Analysis:
These therapies have become more common
- The Allergic Asthma Therapeutics Market is now trending towards biologics and Monoclonal antibodies for the treatment of allergic asthma. These therapies have become more common, since they allow for stronger, more specific impact on the immune reactions implicated in allergic asthma compared to therapies that do not work at the molecular level. The first of such trends is the increasing popularity of precision medicine in the management of chronic ailments.
- Furthermore, there is a clear growth with regard to the multi-drug therapies prevailing in the market. Adding a bronchodilator to an anti-inflammatory, or biologic, provides an improved treatment and effectiveness, as well as ease of use for the patients, which may increase the likelihood of strict compliance to the doses. Such trend can be associated with recent changes in the focus of treatment approaches in healthcare, which aims to create individual and complex treatment plans.
Development in the concentration
- The Allergic Asthma Therapeutics Market has its opportunities for development in the concentration of shares and market niches, especially focused on countries with emerging economies. This is because as more awareness on treatment on Asthma gets to the people, more people in Asia-Pacific, Latin America and the Middle East are being diagnosed with asthma as well as taking their medication. This brings considerable business opportunity in pharmaceutical market since other pharmaceutical industries have the chance to grab the market seat.
- In addition, the emergence of new delivery systems and formulation, smart inhaler and long-acting biologics creates a niche for companies to capture the existing market of improving the patient compliance to drugs. Such developments are expected to increase adherence and the general handling of allergic asthma boosting the market prospects.
Allergic Asthma Therapeutics Market Segment Analysis:
Allergic Asthma Therapeutics Market is segmented on the basis of Drug Class, Route of Administration, Distribution Channel, and Region
By Drug Class, Anti-inflammatory Drugs segment is expected to dominate the market during the forecast period
- The Allergic Asthma Therapeutics Market is classified into major drug classes which have various roles in managing asthma. Corticosteroids are meant to suppress inflammation in the airways and, therefore, are effective in a reducing asthma symptom. Bronchodilators acts by relaxation of the muscles surrounding the air passages and hence enhancing the breathing. There is biologics; monoclonal antibodies which are more selective majorly affiliated to severe asthma and act on precise immune system mechanisms. Combined preparations include the advantages of several treatments into one form, which can benefit patients with treatment plans that are more convenient, and effective.
By Route of Administration, Oral segment expected to held the largest share
- Distribution of allergic asthma therapeutics can be divided mainly into oral, inhalation and intravenous courses. Leukotriene modifiers or corticosteroids are one-pill wonders and well-suited for long-term routine management of asthma. Liquid medications that deliver drugs inhaled directly into the lungs, through use of an inhaler or nebuliser, are used due to symptomatic relief and first choice nature. As a rule, intravenous drugs are used in cases of very severe conditions or for those patients who can badly tolerate any inhaled or oral medication and provide quickly potent effects.
Allergic Asthma Therapeutics Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- The regional study of the Allergic Asthma Therapeutics Market reveals that North America holds the largest market share. A high incidence of allergic asthma in the US and Canada, overall established healthcare system and various effective treatments also play a role in this regard. Moreover, the increasing usage of biologics and monoclonal antibodies, high purchasing capacity in the region and key pharmaceutical companies guarantee sustained market growth in the region.
- It also continues to enjoy investment in research and development primarily aimed at enhancing the quality of life of patients with asthma condition. The sexually weak regulatory framework of North America along with its earliest adoption of novel asthma treatment is an added benefit that solidified its place the largest market for the allergic asthma treatment.
Active Key Players in the Allergic Asthma Therapeutics Market
- AstraZeneca (United Kingdom)
- Boehringer Ingelheim (Germany)
- Eli Lilly and Company (United States)
- GlaxoSmithKline (United Kingdom)
- Merck & Co. (United States)
- Novartis (Switzerland)
- Pfizer (United States)
- Regeneron Pharmaceuticals (United States)
- Sanofi (France)
- Teva Pharmaceutical Industries (Israel)
- Other Active Players
Key Industry Development in Allergic Asthma Therapeutics Market:
- In March 2023, Teva Pharmaceuticals partnered with Rimidi to launch a respiratory patient monitoring initiative at Desert Oasis Healthcare in California, utilizing data from Teva's Digihaler System. The Digihaler, an intelligent inhaler system, provides factual data for asthma control.
Global Allergic Asthma Therapeutics Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 26.4 Billion |
Forecast Period 2024-32 CAGR: |
5.2% |
Market Size in 2032: |
USD 41.66 Billion |
Segments Covered: |
By Drug Class |
|
|
By Route of Administration |
|
||
By Distribution Channel |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Allergic Asthma Therapeutics Market by Drug Class
4.1 Allergic Asthma Therapeutics Market Snapshot and Growth Engine
4.2 Allergic Asthma Therapeutics Market Overview
4.3 Anti-inflammatory Drugs
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Anti-inflammatory Drugs: Geographic Segmentation Analysis
4.4 Bronchodilators
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Bronchodilators: Geographic Segmentation Analysis
4.5 Monoclonal Antibodies (Biologics)
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Monoclonal Antibodies (Biologics): Geographic Segmentation Analysis
4.6 Combination Drugs
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Combination Drugs: Geographic Segmentation Analysis
Chapter 5: Allergic Asthma Therapeutics Market by Route of Administration
5.1 Allergic Asthma Therapeutics Market Snapshot and Growth Engine
5.2 Allergic Asthma Therapeutics Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation Analysis
5.4 Inhalation
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Inhalation: Geographic Segmentation Analysis
5.5 Intravenous
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Intravenous: Geographic Segmentation Analysis
Chapter 6: Allergic Asthma Therapeutics Market by Distribution Channel
6.1 Allergic Asthma Therapeutics Market Snapshot and Growth Engine
6.2 Allergic Asthma Therapeutics Market Overview
6.3 Hospital Pharmacies
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacies: Geographic Segmentation Analysis
6.4 Retail Pharmacies
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail Pharmacies: Geographic Segmentation Analysis
6.5 Online Pharmacies
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Online Pharmacies: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Allergic Asthma Therapeutics Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 GLAXOSMITHKLINE (UNITED KINGDOM)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 NOVARTIS (SWITZERLAND)
7.4 ASTRAZENECA (UNITED KINGDOM)
7.5 MERCK & CO. (UNITED STATES)
7.6 PFIZER (UNITED STATES)
7.7 BOEHRINGER INGELHEIM (GERMANY)
7.8 TEVA PHARMACEUTICAL INDUSTRIES (ISRAEL)
7.9 SANOFI (FRANCE)
7.10 REGENERON PHARMACEUTICALS (UNITED STATES)
7.11 ELI LILLY AND COMPANY (UNITED STATES)
7.12 OTHER ACTIVE PLAYERS
Chapter 8: Global Allergic Asthma Therapeutics Market By Region
8.1 Overview
8.2. North America Allergic Asthma Therapeutics Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Class
8.2.4.1 Anti-inflammatory Drugs
8.2.4.2 Bronchodilators
8.2.4.3 Monoclonal Antibodies (Biologics)
8.2.4.4 Combination Drugs
8.2.5 Historic and Forecasted Market Size By Route of Administration
8.2.5.1 Oral
8.2.5.2 Inhalation
8.2.5.3 Intravenous
8.2.6 Historic and Forecasted Market Size By Distribution Channel
8.2.6.1 Hospital Pharmacies
8.2.6.2 Retail Pharmacies
8.2.6.3 Online Pharmacies
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Allergic Asthma Therapeutics Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Class
8.3.4.1 Anti-inflammatory Drugs
8.3.4.2 Bronchodilators
8.3.4.3 Monoclonal Antibodies (Biologics)
8.3.4.4 Combination Drugs
8.3.5 Historic and Forecasted Market Size By Route of Administration
8.3.5.1 Oral
8.3.5.2 Inhalation
8.3.5.3 Intravenous
8.3.6 Historic and Forecasted Market Size By Distribution Channel
8.3.6.1 Hospital Pharmacies
8.3.6.2 Retail Pharmacies
8.3.6.3 Online Pharmacies
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Bulgaria
8.3.7.2 The Czech Republic
8.3.7.3 Hungary
8.3.7.4 Poland
8.3.7.5 Romania
8.3.7.6 Rest of Eastern Europe
8.4. Western Europe Allergic Asthma Therapeutics Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Class
8.4.4.1 Anti-inflammatory Drugs
8.4.4.2 Bronchodilators
8.4.4.3 Monoclonal Antibodies (Biologics)
8.4.4.4 Combination Drugs
8.4.5 Historic and Forecasted Market Size By Route of Administration
8.4.5.1 Oral
8.4.5.2 Inhalation
8.4.5.3 Intravenous
8.4.6 Historic and Forecasted Market Size By Distribution Channel
8.4.6.1 Hospital Pharmacies
8.4.6.2 Retail Pharmacies
8.4.6.3 Online Pharmacies
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 Netherlands
8.4.7.5 Italy
8.4.7.6 Russia
8.4.7.7 Spain
8.4.7.8 Rest of Western Europe
8.5. Asia Pacific Allergic Asthma Therapeutics Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Class
8.5.4.1 Anti-inflammatory Drugs
8.5.4.2 Bronchodilators
8.5.4.3 Monoclonal Antibodies (Biologics)
8.5.4.4 Combination Drugs
8.5.5 Historic and Forecasted Market Size By Route of Administration
8.5.5.1 Oral
8.5.5.2 Inhalation
8.5.5.3 Intravenous
8.5.6 Historic and Forecasted Market Size By Distribution Channel
8.5.6.1 Hospital Pharmacies
8.5.6.2 Retail Pharmacies
8.5.6.3 Online Pharmacies
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Allergic Asthma Therapeutics Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Class
8.6.4.1 Anti-inflammatory Drugs
8.6.4.2 Bronchodilators
8.6.4.3 Monoclonal Antibodies (Biologics)
8.6.4.4 Combination Drugs
8.6.5 Historic and Forecasted Market Size By Route of Administration
8.6.5.1 Oral
8.6.5.2 Inhalation
8.6.5.3 Intravenous
8.6.6 Historic and Forecasted Market Size By Distribution Channel
8.6.6.1 Hospital Pharmacies
8.6.6.2 Retail Pharmacies
8.6.6.3 Online Pharmacies
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkey
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Allergic Asthma Therapeutics Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Class
8.7.4.1 Anti-inflammatory Drugs
8.7.4.2 Bronchodilators
8.7.4.3 Monoclonal Antibodies (Biologics)
8.7.4.4 Combination Drugs
8.7.5 Historic and Forecasted Market Size By Route of Administration
8.7.5.1 Oral
8.7.5.2 Inhalation
8.7.5.3 Intravenous
8.7.6 Historic and Forecasted Market Size By Distribution Channel
8.7.6.1 Hospital Pharmacies
8.7.6.2 Retail Pharmacies
8.7.6.3 Online Pharmacies
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
Global Allergic Asthma Therapeutics Market |
|||
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 26.4 Billion |
Forecast Period 2024-32 CAGR: |
5.2% |
Market Size in 2032: |
USD 41.66 Billion |
Segments Covered: |
By Drug Class |
|
|
By Route of Administration |
|
||
By Distribution Channel |
|
||
By Region |
|
||
Key Market Drivers: |
|
||
Key Market Restraints: |
|
||
Key Opportunities: |
|
||
Companies Covered in the report: |
|
Frequently Asked Questions :
The forecast period in the Allergic Asthma Therapeutics Market research report is 2024-2032.
GlaxoSmithKline (United Kingdom), Novartis (Switzerland), AstraZeneca (United Kingdom), Merck & Co. (United States), Pfizer (United States), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries (Israel), Sanofi (France), Regeneron Pharmaceuticals (United States), Eli Lilly and Company (United States), and Other Active Players.
The Allergic Asthma Therapeutics Market is segmented into By Drug Class, By Route of Administration, By Distribution Channel and region. By Drug Class, the market is categorized into Anti-inflammatory Drugs, Bronchodilators, Monoclonal Antibodies (Biologics), Combination Drugs. By Route of Administration, the market is categorized into Oral, Inhalation, Intravenous. By Distribution Channel, the market is categorized into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. By region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
The Allergic Asthma Therapeutics Market can be described as the market for drugs intended to cure allergic asthma – a long-term illness of the respiratory tricuspid system which results from the exposure to allergens like pollen, dust, mold, or pet dander. Market includes drugs that are used to relieve conditions including wheezing, coughing, shortness of breath and chest constriction. Available therapies include, anti-inflammatory agents, bronchodilators, biologicals and combination therapies designed to prevent inflammation, widen the airways and minimize life threatening asthmatic episodes.
Allergic Asthma Therapeutics Market Size Was Valued at USD 26.4 Billion in 2023, and is Projected to Reach USD 41.66 Billion by 2032, Growing at a CAGR of 5.2% From 2024-2032.